Drug
Golodirsen clinical trials
Also written SRP-4053 and VYONDYS 53.
- studies test it
- 5
- open now
- 0
- in phase 3
- 2
- first study started
- 2015
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 2
Sarepta Therapeutics, Inc. (3) · Kevin Flanigan (1) · Rare Disease Research, LLC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses golodirsen is read from its arms, and is right about nine times in ten.
Testing it · 5
- An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular DystrophyTerminatedPhase 4Rare Disease Research, LLCNCT04708314Written as Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
- Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)CompletedPhase 3Sarepta Therapeutics, Inc.NCT02500381Written as SRP-4053
- An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyTerminatedPhase 3Sarepta Therapeutics, Inc.NCT03532542Written as Golodirsen
- A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.CompletedPhase 2Kevin FlaniganNCT04179409Written as Vyondys 53
- Phase I/II Study of SRP-4053 in DMD PatientsCompletedPhase 1/2Sarepta Therapeutics, Inc.NCT02310906Written as SRP-4053
Codes
What other systems call golodirsen · ClinicalTrials.gg INT001424
- MeSH (NLM) C000710673golodirsenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 033072U4MZGOLODIRSENConfirmed FDA, NLM
- RxNorm 2267207One source FDA
- NCI Thesaurus C175077GolodirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710673 | golodirsen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 033072U4MZ | GOLODIRSEN | Confirmed FDA, NLM |
| RxNorm | 2267207 | — | One source FDA |
| NCI Thesaurus | C175077 | Golodirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.